NC
NTLA icon

NinePointTwo Capital’s Intellia Therapeutics NTLA Stock Holding History

NinePointTwo Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$370K Buy
+12,147
New +$349K 0.15% 75
2023
Q3 		– Sell
-6,176
Closed -$251K – 297
2023
Q2 		$251K Buy
+6,176
New +$250K 0.1% 136

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

NinePointTwo Capital's NTLA Position: Q4 2023 in Review

NinePointTwo Capital opened a new position in Intellia Therapeutics (NTLA) in Q4 2023: 12,147 shares worth $370K. The stake represents 0.15% of the portfolio and ranks #75 among its holdings. This is a return to the name: NinePointTwo Capital previously reported a position in NTLA as recently as Q2 2023.

NinePointTwo Capital first reported a position in NTLA in Q2 2023 and has held it in 2 quarters since. 292 funds tracked by Wall St. Rank hold NTLA as of Q4 2023.

  • NinePointTwo Capital held 12,147 shares of Intellia Therapeutics worth $370K as of Q4 2023.
  • Intellia Therapeutics was a new NinePointTwo Capital position in Q4 2023.
  • Intellia Therapeutics made up 0.15% of NinePointTwo Capital's portfolio in Q4 2023, its #75 holding.
  • NinePointTwo Capital first reported a position in Intellia Therapeutics in Q2 2023 and has held it in 2 quarters since.
  • 292 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2023.

Based on NinePointTwo Capital's 13F filing for Q4 2023, filed 14 Feb 2024.